Johnson & Johnson Innovative Medicine company-sponsored congress materials which have been accepted for congress presentation at European Association of Urology

Final Analysis of the Phase 1 First‑in‑Human Study of Erda-iDRS, an Erdafitinib Intravesical Drug-Releasing System, in Patients With Non–Muscle‑Invasive Bladder Cancer Harboring Select FGFR Alterations

CARVYKTI_US-SR-10459

rybrevant dossier update - bottom

Lazcluze Dossier Update - bottom

Talvey Digital Dossier banner

CARVYKTI_US-SR-10545

Imaavy Dossier banner

Test-EL

Submit your medical inquiry

Contact J&J Medical Connect for your medical inquiries


This page was last modified on

Additional contact #{index}

janssenscience

Congress Materials

Payer

Dark Blue

oncology

final-analysis-of-the-phase-1-first-in-human-study

Whitelist Modal

Final Analysis of the Phase 1 First‑in‑Human Study of Erda-iDRS, an Erdafitinib Intravesical Drug-Releasing System, in Patients With Non–Muscle‑Invasive Bladder Cancer Harboring Select FGFR Alterations

Connect with us

Connect with us

Live video

Waiting for agent...

Ready to join